Abstracts tagged "Tissue Engineering"

Abstract Number: 1167 • ACR Convergence 2022
Towards an Autologous 3D Skin-like Tissue Harboring Patient-Derived Fibroblasts, Keratinocytes, T-cells and Macrophages
Sasha Shenk¹, Jonathan Garlick¹, Lev Brown², Jamie Riesenberg², Christian Evans², Julia Jaffe Zweifach², Andrew Macklin², Tamar Abel³, Noelle Kosarek⁴, Mengqi Huang⁵, Avi Smith¹, Tammara Wood³, Gretel Torres⁶, Patricia pioli⁶ and Michael Whitfield⁷, ¹Tufts University School of Dental Medicine, Boston, MA, ²Tufts University, Boston, MA, ³Dartmouth College, Hanover, NH, ⁴Dartmouth Geisel School of Medicine, Lebanon, NH, ⁵University of Pittsburgh, Pittsburgh, PN, ⁶Geisel School of Medicine at Dartmouth, Lebanon, NH, ⁷Dartmouth Geisel School of Medicine, Department of Biomedical Data Science, Lebanon, NH
Background/Purpose: Scleroderma (Systemic Sclerosis; SSc) is an autoimmune disease of unknown etiology that is characterized by vascular dysfunction, fibrosis, and inflammation. A lack of human…
Abstract Number: 1801 • ACR Convergence 2020
An Engineered Extracellular Matrix‐rich Decellularized Substrate Based Podocytes Culture System to Study Intracellular Complement Production and Activation
Abhigyan Satyam¹, Maria Tsokos² and George Tsokos², ¹Division of Rheumatology & Clinical Immunology/Beth Israel Deaconess Medical Center/Harvard Medical School, boston, ²Division of Rheumatology & Clinical Immunology/Beth Israel Deaconess Medical Center/Harvard Medical School, Boston, MA
Background/Purpose: Current technologies do not support long-term cell viability, differentiation and maintenance of podocytes. We developed a biophysical approach, termed macromolecular crowding (MMC), to create…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].